Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes

Overactive Bladder

Long-Term Functional Outcomes of S3 Sacral Neuromodulation for the Treatment of Idiopathic Overactive Bladder

Neuromodulation.

Ismail S, Chartier-Kastler E, Perrouin-Verbe MA, Rose-Dite-Modestine J, Denys P, Phé V

doi: 10.1111/ner.12696.

Overactive BladderUrinary Incontinence

Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease

Neurourol Urodyn.

Vurture G, Peyronnet B, Feigin A, Biagioni MC, Gilbert R, Rosenblum N, Frucht S, Di Rocco A, Nitti VW, Brucker BM

doi: 10.1002/nau.23717.

Benign Prostatic Hyperplasia (BPH)Lower Urinary Tract SymptomsOveractive Bladder

Nerve growth factor levels are associated with overactive bladder symptoms and long-term treatment outcome after transurethral resection of the prostate in patients with benign prostate hyperplasia

J Urol.

Hu H, Zhang W, Liu X, Wang H, Fang Z, Liang C, Wang T, Xu K

doi: 10.1016/j.juro.2018.03.130.

Overactive Bladder

Initial clinical experience with selective bladder denervation for refractory overactive bladder

Neurourol Urodyn.

Tu LM, De Wachter S, Robert M, Dmochowski RR, Miller LE, Everaert K

doi: 10.1002/nau.23881.

Overactive Bladder

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Health Qual Life Outcomes.

Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, Schermer CR

doi: 10.1186/s12955-018-0892-0.

Overactive BladderUrinary IncontinencePregnancy and Childbirth

Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder

J Urol.

Tyagi P, Kashyap M, Yoshimura N, Chancellor M, Chermansky CJ

doi: 10.1016/j.juro.2016.11.092.

Overactive Bladder

Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial

Patient.

Herdman M, Nazir J, Hakimi Z, Siddiqui E, Huang M, Pavesi M, MacDiarmid S, Drake MJ, Devlin N

doi: 10.1007/s40271-017-0262-8.

Overactive Bladder

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Neurourol Urodyn.

Mueller ER, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Stoelzel M, Yoon SJ, Al-Shukri S, Rechberger T, Gratzke C

doi: 10.1002/nau.23919.

Lower Urinary Tract SymptomsOveractive Bladder

Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study

Low Urin Tract Symptoms.

Kato D, Tabuchi H, Uno S

doi: 10.1111/luts.12188.

Related content

Long-Term Functional Outcomes of S3 Sacral Neuromodulation for the Treatment of Idiopathic Overactive Bladder

Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease

Nerve growth factor levels are associated with overactive bladder symptoms and long-term treatment outcome after transurethral resection of the prostate in patients with benign prostate hyperplasia

Initial clinical experience with selective bladder denervation for refractory overactive bladder

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder

Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study